Single-Dose DPI Capsule Blend for PDE4 Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing inhalation technologies for PDE4 inhibitors like tanimilast face challenges with systemic side effects and agglomeration issues at higher doses, affecting homogeneity and increasing the risk of adverse events, while current platforms struggle to deliver effective doses efficiently.
Innovation Solution
A single-dose dry powder inhalation device with a specific pharmaceutical composition comprising micronized particles of formula (I) and a carrier, utilizing a mixture of fine and coarse lactose with a ternary agent, is designed to deliver doses between 450 and 600 μg at inspiratory flow rates of 30-65 l/min, enhancing inhalatory performance and reducing systemic absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a higher dose of tanimilast (800 μg) is administered to ensure therapeutic effect, then the therapeutic efficacy is improved, but the risk of systemic side effects and agglomeration increases
Solution Approach 1:
The patent segments the powder composition into distinct particle size fractions: coarse carrier particles (50-250 μm) and fine drug particles (1-15 μm). This segmentation allows the drug to be delivered as extrafine particles that reach distal airways effectively, improving therapeutic efficacy at lower doses and reducing the need for high doses that cause systemic side effects
Solution Approach 2:
The patent applies local quality by creating a heterogeneous particle size distribution where coarse lactose particles serve as carriers in the oropharynx while fine tanimilast particles are delivered to the lungs. This spatial differentiation of particle functions optimizes local drug delivery to the respiratory tract, enhancing efficacy while minimizing systemic absorption
2Reliability
If a higher dose of tanimilast (800 μg) is administered to ensure therapeutic effect, then the therapeutic efficacy is improved, but the homogeneity of the blend deteriorates due to agglomeration
Solution Approach 1:
The patent segments the formulation into coarse carrier particles and fine drug particles with distinct size ranges. This segmentation prevents agglomeration by maintaining physical separation between drug particles and carrier particles throughout manufacturing and storage, ensuring homogeneous blends even at optimized lower doses
Solution Approach 2:
The patent uses coarse lactose particles as intermediary carriers that physically separate and distribute fine tanimilast particles throughout the blend. This intermediary approach prevents direct contact and agglomeration of drug particles, maintaining manufacturing precision and dose uniformity
3Adaptability or versatility
If a multidose inhaler platform is used to deliver the drug, then the device versatility is improved, but the risk of contamination and dose accuracy deteriorates
Solution Approach 1:
The patent employs a disposable single-dose capsule that is discarded after one use. This eliminates contamination risks associated with multidose devices and ensures dose accuracy by preventing drug degradation and cross-contamination. The low cost of the single-use capsule makes this approach economically viable
4Ease of manufacture
If the drug is delivered as larger particles to simplify manufacturing, then the ease of manufacture is improved, but the lung deposition efficiency deteriorates
Solution Approach 1:
The patent segments the drug delivery system into two particle size populations: coarse carrier particles for easy handling and manufacturing, and fine drug particles (1-15 μm) for efficient lung deposition. This segmentation allows simple manufacturing processes while achieving high lung delivery efficiency through the fine particle fraction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device improves respirable fraction by 25-35% and extrafine particle delivery, allowing lower doses with maintained therapeutic effect, reducing systemic absorption and agglomeration risks, and enhancing lung deposition.
Implementation Method 1
a single-dose dry powder inhalation device... wherein the inspiratory flow rate of said inhalation device is between 30 l/min and 65 l/min at 4 kPa of pressure drop
Implementation Method 2
extrafine particles are capable of reaching the distal tract of the respiratory tree and hence improving small airways outcomes
Data Source
AI summary
The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition loaded in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.